Unveiling the potential biochemical effects of selected heterocyclic compounds as human Type-A γ-aminobutyric acid (GABA A) Modulator: An Insilico Approach

Abstract

Background: Investigating the bioactivities of zuranolone derivatives as Type-A γ-aminobutyric acid inhibitors which will thereby down-regulate postpartum depression is considered a crucial study. Method: This study is aimed at investigating the biochemical activities of 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3‑hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile derivatives against type-A γ-aminobutyric acid (GABA A) which will thereby enhance the activity of γ-aminobutyric acid (GABA) in human central nervous system. Results: ) and energy gap and the results were reported appropriately. The molecular docking investigation was carried out on the studied compounds and Type-A γ-aminobutyric acid (pdb id: 4cof) and the compounds 3 with calculated binding affinity value of -7.32433319kcal/mol as well as pi-H as the non-bonding interaction were observed which therefore confirm the potential ability of compound to inhibit the target than other studied compound. Also, compound 1 and reference compound were subjected to molecular dynamic simulation study and the actual binding energy for the selected compounds were obtained and reported. Conclusion: Our findings from this work may open door for the design of several 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-(benzyloxy)-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile derivatives as potential Type-A γ-aminobutyric acid inhibitors.